The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shestakova M.V.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Sukhareva O.Iu.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Chernova T.O.

FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava RF

Shmushkovich I.A.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr" MZ RF, Moskva

Aleksandrov A.A.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva

Il'in A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Dedov I.I.

Endocrinology Research Centre

A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition

Authors:

Shestakova M.V., Sukhareva O.Iu., Chernova T.O., Shmushkovich I.A., Aleksandrov A.A., Il'in A.V., Dedov I.I.

More about the authors

Journal: Therapeutic Archive. 2013;85(8): 49‑55

Read: 2165 times

Download PDF (RU)
Contact the author
Table of contents

A COMBINATION OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR AND METFORMIN IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS: EFFECTIVE CONTROL OF GLYCEMIA, WEIGHT, AND QUANTITATIVE BODY COMPOSITION
A COMBINATION OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR AND METFORMIN IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS: EFFECTIVE CONTROL OF GLYCEMIA, WEIGHT, AND QUANTITATIVE BODY COMPOSITION

To cite this article:

Shestakova MV, Sukhareva OIu, Chernova TO, Shmushkovich IA, Aleksandrov AA, Il'in AV, Dedov II. A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition. Therapeutic Archive. 2013;85(8):49‑55. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Modu­lation of oxidative stress as an early symptom of sarcopenia in type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(10):108-116
Rela­tionship between meta­bolic syndrome components and pathology of the red border of the lips and oral mucosa. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):58-63
Classical and new athe­rosclerosis biomarkers in elde­rly patients with type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2025;(3):87-95
Asso­ciation of adipokines and sleep diso­rders among the 25—44 year-old people. Russian Journal of Preventive Medi­cine. 2025;(8):41-47
Ethnic aspe­cts of risk factors for the type 2 diabetes mellitus deve­lopment in the overweight women of the Pribaikalsky region. Russian Journal of Preventive Medi­cine. 2025;(8):56-62
Asse­ssment of biomarker levels in patients with STEMI, depe­nding on the presence of cardiovascular events. Russian Journal of Preventive Medi­cine. 2025;(8):96-101
Sex and age characteristics of stroke risk factors in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):89-97
Possibilities of oral form of cyanocobalamin in pharmacological correction of vita­min B12 defi­ciency deve­loped in patients with type 2 diabetes mellitus during treatment with metformin. Russian Journal of Preventive Medi­cine. 2025;(9):64-69
Abstract:

Aim. To study the impact of intensified therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor vilagliptin or sulfonylurea (SU) on the control of glycemia, weight, and quantitative body composition in patients with type 2 diabetes mellitus (DM-2) who have failed to achieve compensation during metformin monotherapy. Subjects and methods. Forty patients (mean age 55.0 (range 53.0-60.7) years; disease duration 2.0 (range 1.1-5.0) years) with poor glycemic control (7%

Keywords:

type 2 diabetes mellitus
quantitative body composition
adiponectin
vildagliptin

Authors:

Shestakova M.V.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Sukhareva O.Iu.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Chernova T.O.

FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava RF

Shmushkovich I.A.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr" MZ RF, Moskva

Aleksandrov A.A.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva

Il'in A.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Dedov I.I.

Endocrinology Research Centre

Close metadata

References:

  1. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
  2. Dedov I.I., Shestakova M.V., Sukhareva O.Yu. Innovatsii v lechenii sakharnogo diabeta 2-go tipa: primenenie inkretinov. Ter arkh 2010; 10: 5-10.
  3. International Diabetes Federation. Treatment Algorithm for People with Type 2 Diabetes. Dostupno na http://www.idf.org/treatment-algorithm-people-type-2-diabetes.
  4. Dedov I.I., Shestakova M.V., Ametov A.S. i dr. Konsensus soveta ekspertov Rossiiskoi assotsiatsii endokrinologov po initsiatsii i intensifikatsii sakharosnizhayushchei terapii SD-2-go tipa. Sakharnyi diabet 2011; 4: 6-17.
  5. Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
  6. Hubert H.B., Feinleib M., McNamara P.T., Castell W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants of the Framingham Heart Study. Circulation 1983; 67: 968-977.
  7. Dedov I.I., Mel'nichenko G.A., Romantsova T.I. Patogeneticheskie aspekty ozhireniya. Ozhirenie i metabolizm 2004; 1: 3-9.
  8. Koenig W., Khuseyinova N., Baumert J. et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middleaged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006; 48: 1369-1377.
  9. Mazess R.B., Barden H.S. Measurement of bone by dual-photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DEXA). Ann Chir Gynaecol 1988; 77 (5-6): 197-203.
  10. Holst J. The physiology and pharmacology of incretins in type 2 diabetes. Diabetes Obes Metab 2008; 10 (Suppl 3): 14-21.
  11. Balas B., Baig M.R. The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients. J Clin Endocrinol Metabol 2007; 92 (4): 1249 -1255.
  12. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin System. Endocrine Rev 2012; 33 (2): 187-215.
  13. Butrova S.A., Dzgoeva F.Kh. Vistseral'noe ozhirenie - klyuchevoe zveno metabolicheskogo sindroma. Ozhirenie i metabolizm 2004; 1: 10-13.
  14. Despres J.P. Inflammation and cardiovascular disease: is abdominal obesity the missing link? Int J Obes 2003; 27 (Suppl): 22-24.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.